Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients

<p>INTRODUCTION Rheumatoid Arthritis is a systemic inflammatory disease and classical disease-modifying anti-rheumatic drugs (cDMARDs) have proven efficacy. It is unknown what impact cDMARDs might have on dementia as an outcome. </p> <p>METHODS Incident diagnoses of Rheumatoid Art...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Judge, AD, Garriga-Fuentes, C, Arden, NK, Lovestone, S, Prieto-Alhambra, D, Cooper, C, Edwards, CJ
Μορφή:	Journal article
Έκδοση:	Elsevier 2017

Παρόμοια τεκμήρια

The effects of disease-modifying antirheumatic drugs on dementia in patients with rheumatoid arthritis: a population-based propensity-matched cohort study over 15 years
ανά: Judge, A, κ.ά.
Έκδοση: (2017)

The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
ανά: Edwards, C, κ.ά.
Έκδοση: (2007)

Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom
ανά: Judge, A, κ.ά.
Έκδοση: (2015)

Temporal Trends In The Prescribing Of Disease Modifying Anti-Rheumatic Drugs For Rheumatoid Arthritis and The Impact Of Guidelines.
ανά: Wallace, G, κ.ά.
Έκδοση: (2013)

Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: an analysis of UK electronic medical records
ανά: Hawley, S, κ.ά.
Έκδοση: (2019)

Impact of biologic therapies on need for hip and knee replacement among rheumatoid arthritis and non-rheumatoid arthritis patients in Ontario, Canada: An interrupted time-series analysis
ανά: Hawley, S, κ.ά.
Έκδοση: (2017)

Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.
ανά: Emery, P, κ.ά.
Έκδοση: (1994)

The impact of rheumatoid arthritis on the risk of adverse events following joint replacement: a real-world cohort study
ανά: Burn E, κ.ά.
Έκδοση: (2018-06-01)

Descriptive epidemiology of hip and knee replacement among rheumatoid arthritis patients in England and Wales: variation by age, sex, geography and socioeconomic status
ανά: Hawley, S, κ.ά.
Έκδοση: (2017)

Total hip and knee replacement among incident osteoarthritis and rheumatoid arthritis patients within the UK Clinical Practice Research Datalink (CPRD) compared to hospital episode statistics (HES): a validation study
ανά: Hawley, S, κ.ά.
Έκδοση: (2016)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis.
ανά: Thao H P Nguyen, κ.ά.
Έκδοση: (2022-01-01)

Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis
ανά: Wenhui Xie, κ.ά.
Έκδοση: (2024-02-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
ανά: Xia Y, κ.ά.
Έκδοση: (2016-05-01)

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
ανά: Abhishek Zanwar, κ.ά.
Έκδοση: (2017-01-01)

The Impact of Biologic Therapy Introduction on Hip and Knee Replacement Among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis Using the Clinical Practice Research Datalink
ανά: Hawley, S, κ.ά.
Έκδοση: (2016)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
ανά: Anne Mirjam Kerola, κ.ά.
Έκδοση: (2021-05-01)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis.
ανά: Gia Deyab, κ.ά.
Έκδοση: (2021-01-01)

Disease-Modifying Antirheumatic Diets: The New Treatment Modalities for Rheumatoid Arthritis
ανά: Shweta Khanna, κ.ά.
Έκδοση: (2018-07-01)

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
ανά: Hawley, S, κ.ά.
Έκδοση: (2019)

Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs
ανά: D. S. Novikova, κ.ά.
Έκδοση: (2020-01-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
ανά: Yu. V. Muraviev, κ.ά.
Έκδοση: (2018-12-01)

Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
ανά: O. V. Shatalova, κ.ά.
Έκδοση: (2017-04-01)

Lung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
ανά: Yuriy Vladimirovich Murav'ev, κ.ά.
Έκδοση: (2010-12-01)

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
ανά: Gregory Fleury, κ.ά.
Έκδοση: (2017-12-01)

Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: an interrupted time-series analysis
ανά: Hawley, S, κ.ά.
Έκδοση: (2017)

Abstract 6 — Are Disease-Modifying Antirheumatic Drugs: for Rheumatoid Arthritis Associated with a Lower Risk of Dementia? A Systematic Review with Meta-Analysis
ανά: Wenhui Xie, κ.ά.
Έκδοση: (2023-11-01)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
ανά: Sofie Bliddal, κ.ά.
Έκδοση: (2017-07-01)

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
ανά: Yinzhu Jin, κ.ά.
Έκδοση: (2023-11-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
ανά: Yinzhu Jin, κ.ά.
Έκδοση: (2017-07-01)

Dynamics of T- and B-lymphocytes in patients with rheumatoid arthritis, receiving biological disease-modifying antirheumatic drugs
ανά: A. V. Martynova, κ.ά.
Έκδοση: (2022-02-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
ανά: A. O. Bobkova, κ.ά.
Έκδοση: (2023-07-01)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
ανά: Soo-Kyung Cho, κ.ά.
Έκδοση: (2023-07-01)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
ανά: Smolen, J, κ.ά.
Έκδοση: (2017)

The impact of rheumatoid arthritis on length of stay and health care costs following knee and hip replacements: a CPRD-HES linked study
ανά: Burn, E, κ.ά.
Έκδοση: (2017)

The impact of rheumatoid arthritis on the risk of adverse events following joint replacement: a real-world cohort study
ανά: Burn, E, κ.ά.
Έκδοση: (2018)

Chronic Heart Failure in Early Rheumatoid Arthritis Patients Prior to Basic Antirheumatic Therapy
ανά: I. G. Kirillova, κ.ά.
Έκδοση: (2020-03-01)

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.
ανά: Griffiths, R, κ.ά.
Έκδοση: (2001)

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
ανά: Griffiths, R, κ.ά.
Έκδοση: (2000)

THU0108 Patient reported outcome measures following knee and hip replacement for individuals with rheumatoid arthritis: evidence from routinely-collected data
ανά: Burn, E, κ.ά.
Έκδοση: (2018)

Comparative effectiveness of tumour necrosis factor inhibitor therapy vs. conventional synthetic dmards on need for joint replacement among rheumatoid arthritis patients: A propensity score matched analysis of UK registry data
ανά: Hawley, S, κ.ά.
Έκδοση: (2018)